What does liquid biopsy actually look like in India right now? We asked 11 oncologists, lab scientists, and industry leaders across 9 institutions. It’s already influencing treatment decisions in NSCLC and colorectal cancer monitoring. But the bigger challenges often begin before the sample reaches the lab. Cost, standardization, and evidence gaps matter too - and not always in expected ways. And experts don’t fully agree on how quickly the field will scale, or what comes after ctDNA. Straight from the people building and running these labs: where liquid biopsy stands today, what’s holding it back, and what’s next.